Molecular Test Identifies Hormone-Responsive Breast Cancer

In addition, BCI appears to demonstrate significant predictive utility in determining which patients will benefit from neoadjuvant (preoperative) chemotherapy and are candidates for breast conserving surgery (BCS).

bioTheranostics, Inc. (San Diego, CA, USA) a bioMerieux (Marcy l'Etoile, France) company that develops oncology diagnostic tests to direct personalized treatment, announced results from studies that demonstrated the increased clinical utility of the Breast Cancer Index(SM) (BCI). Data from the studies, presented at the Cancer Therapy and Research Center –American Association for Cancer Research (CTRC-AACR) San Antonio Breast Cancer Symposium (SABCS) held from December 6-10 in San Antonio, (TX, USA) suggest that BCI, with its novel mechanism of action, provides oncologists with insight into the risk of late recurrence for estrogen receptor positive and lymph node negative (ER+, LN-) breast cancer patients.

In addition, BCI appears to demonstrate significant predictive utility in determining which patients will benefit from neoadjuvant (preoperative) chemotherapy, and are candidates for breast conserving surgery (BCS).

Mark Erlander, PhD, CSO of bioTheranostics said, "Although first-generation multigene signatures provide prognostic information, their utility is strongest for predicting relapse within five years of the breast cancer diagnosis. Breast Cancer Index demonstrates sustainable prognostic power and particularly addresses the unmet medical need of late recurrence."

Neoadjuvant chemotherapy is very important for physicians because oncologists want to identify which patients would have the greatest likelihood of being eligible for breast conserving surgery after neoadjuvant chemotherapy.

Related Links:
bioTheranostics
bioMerieux